{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T10:57:09Z","timestamp":1772535429373,"version":"3.50.1"},"reference-count":13,"publisher":"Informa UK Limited","issue":"4","funder":[{"DOI":"10.13039\/100010104","name":"Zhengzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["XTCX2023010"],"award-info":[{"award-number":["XTCX2023010"]}],"id":[{"id":"10.13039\/100010104","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Talent Research Fund of the First Affiliated Hospital of Zhengzhou University","award":["82270225"],"award-info":[{"award-number":["82270225"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,4,2]]},"DOI":"10.1080\/14712598.2024.2333793","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T13:43:27Z","timestamp":1710942207000},"page":"221-223","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting"],"prefix":"10.1080","volume":"24","author":[{"given":"Lijie","family":"Han","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizhou","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijie","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxing","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-4385","authenticated-orcid":false,"given":"Jifeng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_7_3_1","first-page":"Abstract 2877","article-title":"Assessment of outcomes of consolidation therapy by number of cycles of Blinatumomab received in newly diagnosed measurable residual disease negative patients with B-Lineage acute lymphoblastic leukemia: In the ECOG-ACRIN E1910 randomized phase III national clinical trials network trial","author":"Luger S","year":"2023","unstructured":"Luger S, Mattison R, Paietta E, et al. Assessment of outcomes of consolidation therapy by number of cycles of Blinatumomab received in newly diagnosed measurable residual disease negative patients with B-Lineage acute lymphoblastic leukemia: In the ECOG-ACRIN E1910 randomized phase III national clinical trials network trial. ASH. 2023:Abstract 2877. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper189648.html","journal-title":"ASH"},{"issue":"1","key":"e_1_3_7_4_1","first-page":"826","article-title":"Sequential chemotherapy and Blinatumomab to improve minimal residual disease in adult Ph- B-Lineage acute lymphoblastic leukemia. Final results of the phase II Gimema LAL2317 Trial","volume":"142","author":"Chiaretti S","year":"2023","unstructured":"Chiaretti S, Santoro A, Spinelli O, et al. Sequential chemotherapy and Blinatumomab to improve minimal residual disease in adult Ph- B-Lineage acute lymphoblastic leukemia. Final results of the phase II Gimema LAL2317 Trial. ASH. 2023;142(Supplement 1):826\u2013826. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper174973.html","journal-title":"ASH"},{"issue":"1","key":"e_1_3_7_5_1","first-page":"4243","article-title":"Reduced-dose chemotherapy followed by Blinatumomab as induction therapy in treatment of newly diagnosed Philadelphia chromosome-negative B-Cell precursor acute lymphoblastic leukemia - interim results from a multicenter, single-arm, phase 2 study","volume":"142","author":"Lu J","year":"2023","unstructured":"Lu J, Qiu H, Lu X, et al. Reduced-dose chemotherapy followed by Blinatumomab as induction therapy in treatment of newly diagnosed Philadelphia chromosome-negative B-Cell precursor acute lymphoblastic leukemia - interim results from a multicenter, single-arm, phase 2 study. ASH. 2023;142(Supplement 1):4243\u20134243. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper174831.html","journal-title":"ASH"},{"issue":"1","key":"e_1_3_7_6_1","first-page":"964","article-title":"Dose reduced chemotherapy in sequence with Blinatumomab for newly diagnosed older patients with Ph\/BCR: ABL negative B-Precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial","volume":"142","author":"Goekbuget N","year":"2023","unstructured":"Goekbuget N, Faul C, Subklewe M, et al. Dose reduced chemotherapy in sequence with Blinatumomab for newly diagnosed older patients with Ph\/BCR: ABL negative B-Precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial. ASH. 2023;142(Supplement 1):964\u2013964. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper180472.html","journal-title":"ASH"},{"issue":"1","key":"e_1_3_7_7_1","first-page":"2827","article-title":"Chemotherapy-free combination of Blinatumomab and Ponatinib in adults with newly diagnosed Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: updates from a phase II trial","volume":"142","author":"Haddad F","year":"2023","unstructured":"Haddad F, Jain N, Short N, et al. Chemotherapy-free combination of Blinatumomab and Ponatinib in adults with newly diagnosed Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: updates from a phase II trial. ASH. 2023;142(Supplement 1):2827\u20132827. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper188064.html","journal-title":"ASH"},{"key":"e_1_3_7_8_1","first-page":"Abstract 2425","article-title":"Updated results from a phase II study of hyper-CVAD, with or without Inotuzumab Ozogamicin, and sequential blinatumomab in patients with newly diagnosed B-Cell acute lymphoblastic leukemia","author":"Nguyen D","year":"2023","unstructured":"Nguyen D, Short N, Jain N, et al. Updated results from a phase II study of hyper-CVAD, with or without Inotuzumab Ozogamicin, and sequential blinatumomab in patients with newly diagnosed B-Cell acute lymphoblastic leukemia. ASH. 2023:Abstract 2425. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper190902.html","journal-title":"ASH"},{"issue":"1","key":"e_1_3_7_9_1","first-page":"2868","article-title":"A phase II study of low-intensity chemotherapy (mini-hyper-CVD) and ponatinib followed by Blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"142","author":"Jen W","year":"2023","unstructured":"Jen W, Jabbour E, Haddad F, et al. A phase II study of low-intensity chemotherapy (mini-hyper-CVD) and ponatinib followed by Blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. ASH. 2023;142(Supplement 1):2868\u20132868. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper182997.html","journal-title":"ASH"},{"issue":"1","key":"e_1_3_7_10_1","first-page":"966","article-title":"Blinatumomab in combination with immune checkpoint inhibitors (ICIs) of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-Cell acute lymphoblastic leukemia (ALL): results of a phase I study","volume":"142","author":"Webster J","year":"2023","unstructured":"Webster J, Rimando J, Zeidan A, et al. Blinatumomab in combination with immune checkpoint inhibitors (ICIs) of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-Cell acute lymphoblastic leukemia (ALL): results of a phase I study. ASH. 2023;142(Supplement 1):966\u2013966. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper191109.html","journal-title":"ASH"},{"issue":"1","key":"e_1_3_7_11_1","first-page":"4242","article-title":"A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with relapsed\/refractory T-Cell acute lymphoblastic leukemia","volume":"142","author":"Murthy G","year":"2023","unstructured":"Murthy G, Duvall A, Leonard J, et al. A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with relapsed\/refractory T-Cell acute lymphoblastic leukemia. ASH. 2023;142(Supplement 1):4242\u20134242. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper187468.html","journal-title":"ASH"},{"issue":"1","key":"e_1_3_7_12_1","first-page":"1541","article-title":"A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed\/refractory acute myeloid leukemia","volume":"142","author":"Murthy G","year":"2023","unstructured":"Murthy G, Badar T, Yi C, et al. A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed\/refractory acute myeloid leukemia. ASH. 2023;142(Supplement 1):1541\u20131541. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper187721.html","journal-title":"ASH"},{"issue":"1","key":"e_1_3_7_13_1","first-page":"322","article-title":"A phase II study of vibecotamab, a CD3-CD123 bispecific T-Cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-Positive AML","volume":"142","author":"Nguyen D","year":"2023","unstructured":"Nguyen D, Wang S, Jorgensen J, et al. A phase II study of vibecotamab, a CD3-CD123 bispecific T-Cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-Positive AML. ASH. 2023;142(Supplement 1):322\u2013322. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper190693.html","journal-title":"ASH"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173302"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2333793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T12:37:38Z","timestamp":1728563858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2333793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,2]]}},"alternative-id":["10.1080\/14712598.2024.2333793"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2333793","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}